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Parkinson’s disease (PD) is the most common movement disorder characterized by death of dopaminergic neurons in the substantia nigra pars compacta. Sophisticated genetic 
analysis has revealed several PD-associated genes including those encoding α-synuclein, parkin, PINK1, DJ-1, LRRK2, and ATP13A2 (see table). Diverse environmental factors 
in conjunction with genetic risk factors lead to PD pathogenesis, although the exact mechanisms are still under investigation. This SnapShot summarizes the roles that proteins 
encoded by PD-associated genes play in both common and divergent mechanisms of PD pathogenesis.
Death of Dopaminergic Neurons
Unlike most other brain neurons, the dopaminergic neurons of the substantia nigra use L-type Ca2+ channels (containing a distinctive Cav 1.3 pore-forming subunit, Cacna1d) for pace 
making, resulting in increased ATP consumption and Ca2+ influx. Ca2+ enters the endoplasmic reticulum (ER) via a high-affinity smooth ER Ca2+ (SERCA) pump. Ca2+ flows back into 
the cytoplasm through inositol trisphosphate receptors (IP3R) and ryanodine receptors (RyR) forming a high-concentration Ca
2+ zone near mitochondria. Mitochondria in dopamin-
ergic neurons take up Ca2+ via the Ca2+ uniporter, whereas mitochondrial Ca2+ efflux is mediated by the Na+/Ca2+ exchanger (NCX). Mitochondria are a key target in PD and impaired 
mitochondria contribute to death of dopaminergic neurons. Due to their unique Cav 1.3 calcium channels, dopaminergic neurons are more vulnerable to environmental toxins, such 
as 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP). MPTP selectively kills dopaminergic neurons by blocking the activity of mitochondrial complex I and has been used to cre-
ate animal models of PD. Once monoamine oxidase B (MAOB) metabolizes MPTP into 1-methyl-4-phenyl-pyridium (MPP+), MPP+ is transported and concentrated in mitochondria by 
the dopamine transporter. This leads to inhibition of mitochondrial complex I, eventual depolarization of the mitochondrial membrane, and opening of the mitochondrial permeability 
transition pore (mPTP). This results in release of mitochondrial cell death effectors such as cytochrome c and apoptosis-inducing factor (AIF). Ultimately death of the dopaminergic 
neuron ensues through various cell death cascades including caspase-dependent and caspase-independent pathways, ER stress, neuronal nitric oxide synthase (nNOS) activation, 
DNA damage, poly(ADP-ribose) polymerase (PARP) activation, and GAPDH modification. Microglial activation also contributes to the demise of dopaminergic neurons.
PD Genes and Molecular Pathogenesis
Autosomal-Dominant
α-Synuclein: Even though the physiological function of α-synuclein is still unclear, numerous studies indicate its association with membranes, synaptic vesicle recycling, 
dopamine neurotransmission, and lipid interactions. This protein is the major structural component of Lewy bodies, which are the pathological hallmark of PD. Identification of 
genetic abnormalities in the α-synuclein gene have implicated the protein encoded by this gene in the pathophysiology of PD. Native unfolded or altered α-synuclein monomers 
with genetic modifications (A53T, E46K, A30P) form toxic intermediates such as oligomers and fibrils, which eventually form Lewy bodies. Triplication of the α-synuclein gene 
(X3) can also lead to PD due to the simple increase in the steady-state level of wild-type α-synuclein. In sporadic PD, reactive oxygen species (ROS), reactive nitrogen species 
(RNS), and aging play a role in the aggregation of α-synuclein. ROS/RNS production, disruption of macroautophagy, mitochondrial dysfunction, and proteasome inhibition can 
also be triggered by mutant or aggregated α-synuclein. The histone deacetylase, Sirtuin2 (SIRT2), may also contribute to PD pathogenesis.
LRRK2: LRRK2 consists of diverse domains, including a leucine-rich repeat, a Roc GTPase domain, a COR (C-terminal of Ras) domain, a kinase domain, and a WD40-repeat. 
LRRK2 is localized in the cytoplasm and is associated with membranous structures including mitochondria, the ER, and synaptic vesicles. Familial mutants of LRRK2 result 
in a gain of function and neuronal toxicity that is kinase dependent and regulated by the chaperones CHIP and HSP90. These chaperones control LRRK2 levels through the 
ubiquitin-proteasome system. Moesin is a putative LRRK2 substrate. Functional studies implicate LRRK2 in neurite outgrowth and the endocytosis of synaptic vesicles. 4E-BP 
is a putative LRRK2 substrate, suggesting that LRRK2 is involved in translation. Data suggest that LRRK2 may also regulate mitochondrial function. Disease-causing mutations 
in human LRRK2 consistently cause α-synuclein pathology.
Autosomal-Recessive
PINK1: Little is known about the function of PINK1, other than that it is thought to be a mitochondrial kinase that acts upstream of parkin in the PD pathogenesis cascade. 
Disease-causing mutations in PINK1 may lead to a loss of function. The mitochondrial chaperone, TRAP1, and the serine protease, HtrA2, are putative PINK1 substrates that 
play important roles in regulating mitochondrial function and mitochondrial-dependent cell death pathways. PINK1 may also physiologically regulate Ca2+ efflux from the mito-
chondria via NCK.
DJ-1: DJ-1 is a molecular chaperone with multiple functions. Disease-causing mutations in DJ-1 may lead to a loss of function. DJ-1 regulates ROS levels by acting as an atypical 
peroxiredoxin-like peroxidase and also modulates RNA metabolism and gene transcription. In addition, DJ-1 may bind to Daxx/apoptosis signal-regulating kinase1 (ASK1) and 
inhibit ASK1 activity and cell death. DJ-1 is also involved in a Parkin-PINK1-DJ-1 (PPD) complex that promotes the degradation of unfolded proteins.
Parkin: Mutations in the parkin gene and posttranslational modifications to the protein, such as phosphorylation or S-nitrosylation (SNO) by ROS/RNS, block parkin’s ability to 
function as an E3 ubiquitin ligase. This leads to the accumulation of its substrates, including AIMP2, FBP-1, and others, which are somehow involved in mitochondrial dysfunction 
and neuronal toxicity. Parkin uses poly-K48 ubiquitin linkages to promote degradation of its substrates. Parkin also uses poly-K63 ubiquitin linkages or mono-ubiquitination to 
regulate intracellular signaling, receptor trafficking, and the formation of inclusions. Parkin acts downstream of PINK1 in genetic models and appears to play a role in the clear-
ance of mitochondria by autophagy (mitophagy).
ATP13A2: ATP13A2 is a large lysosomal P-type ATPase. Although functional studies are at a very early stage, it is thought that ATP13A2 and the PD susceptibility gene encoding 
β-glucocerebrosidase (GBA) may be involved in the clearance of α-synuclein aggregates.
Abbreviations
AD, autosomal-dominant; AR, autosomal-recessive; 4E-BP, eukaryotic initiation factor 4E (eIF4E)-binding protein; PSF, pyrimidine tract-binding protein-associated splicing fac-
tor; p54nrb, p54 nuclear RNA-binding protein; GPX4, glutathione peroxidase 4; MAPK8IP1, mitogen-activated protein kinase 8-interacting protein 1; Ub, ubiquitin.
RefeReNceS
Abeliovich, A. (2007). Parkinson’s disease: pro-survival effects of PINK1. Nature 448, 759–760.
Biskup, S., and West, A.B. (2009). Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson’s disease. Biochim. Biophys. Acta 1792, 625–633.
Chan, C.S., Gertler, T.S., and Surmeier, D.J. (2009). Calcium homeostasis, selective vulnerability and Parkinson’s disease. Trends Neurosci. 32, 249–256.
Dawson, T.M., and Dawson, V.L. (2003). Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302, 819–822.
Gasser, T. (2009). Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 11, e22.
Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S., Hill, K.J., Caldwell, K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.C., et al. (2009). Alpha-synuclein is part of a 
diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308–315.
Gupta, A., Dawson, V.L., and Dawson, T.M. (2008). What causes cell death in Parkinson’s disease? Ann. Neurol. 64 (Suppl 2), S3–S15.
Lees, A.J., Hardy, J., and Revesz, T. (2009). Parkinson’s disease. Lancet 373, 2055–2066.
Lim, K.L., and Ng, C.H. (2009). Genetic models of Parkinson disease. Biochim. Biophys. Acta 1792, 604–615.
Schapira, A.H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol. 7, 97–109.
